{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:08:50Z","timestamp":1792066130013,"version":"4.4.0"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T00:00:00Z","timestamp":1520294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00c3\u00ada y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["SAF2015-64629-C2-1-R"],"award-info":[{"award-number":["SAF2015-64629-C2-1-R"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ejmech.2018.03.007","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T12:13:48Z","timestamp":1520252028000},"page":"206-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Polypharmacology in HIV inhibition: can a drug with simultaneous action against two relevant targets be an alternative to combination therapy?"],"prefix":"10.1016","volume":"150","author":[{"given":"Sonia","family":"de Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4978-6468","authenticated-orcid":false,"given":"Mar\u00eda-Jos\u00e9","family":"Camarasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.03.007_bib1","series-title":"UNAIDS\/WHO Global HIV\/AIDS Online Database","author":"WHO","year":"2016"},{"key":"10.1016\/j.ejmech.2018.03.007_bib2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nrd2336","article-title":"HIV drug development: the next 25 years","volume":"6","author":"Flexner","year":"2007","journal-title":"Nature Rev. Drug Discov"},{"key":"10.1016\/j.ejmech.2018.03.007_bib4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/jmv.21034","article-title":"Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs","volume":"80","author":"Perno","year":"2008","journal-title":"J.\u00a0Med. Virol"},{"key":"10.1016\/j.ejmech.2018.03.007_bib5","doi-asserted-by":"crossref","first-page":"20839","DOI":"10.3390\/molecules191220839","article-title":"Hybrid curcumin compounds: a new strategy for cancer treatment","volume":"19","author":"Teiten","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2018.03.007_bib6","series-title":"The Practice of Medicinal Chemistry. Chapt 27","article-title":"Multi-target drugs: strategies and challenges for medicinal chemistry","author":"Rankovic","year":"2008"},{"key":"10.1016\/j.ejmech.2018.03.007_bib7","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. An emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1021\/cb8001792","article-title":"Design and applications of bifunctional small molecules: why two heads Are better than one","volume":"3","author":"Corson","year":"2008","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.03.007_bib9","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1039\/C4MB00147H","article-title":"Old Drugs with New Tricks\u201d: exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets","volume":"10","author":"Kang","year":"2014","journal-title":"Mol. BioSyst"},{"key":"10.1016\/j.ejmech.2018.03.007_bib10","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1021\/jm00010a008","article-title":"Synthesis and anti-HIV activity of [AZT]-[TSAO-T] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase","volume":"38","author":"Vel\u00e1zquez","year":"1995","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib11","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1021\/jm960056x","article-title":"Complexes of HIV-1 reverse transcriptase with Inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors","volume":"39","author":"Hopkins","year":"1996","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib12","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/0006-2952(88)90366-8","article-title":"Alpha, beta- and beta, gamma-methylene 5'-phosphonate derivatives of 3'-azido-2',3'-dideoxythymidine-5'-triphosphate. Correlation between affinity for reverse transcriptase, susceptibility to hydrolysis by phosphodiesterases and anti-retrovirus activity","volume":"37","author":"Balzarini","year":"1988","journal-title":"Biochem. Pharmacol"},{"key":"10.1016\/j.ejmech.2018.03.007_bib13","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1021\/jm991092+","article-title":"Potential multifunctional inhibitors of hiv-1 reverse transcriptase. Novel [AZT]-[TSAO-T] and [d4T-]-[TSAO-T] heterodimers modified in the linker and in the dideoxynucleoside region","volume":"42","author":"Vel\u00e1zquez","year":"1999","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib14","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1021\/jm00060a013","article-title":"Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT","volume":"36","author":"McGuigan","year":"1993","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib15","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1073\/pnas.89.10.4392","article-title":"2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5'-(4'-amino-1',2'- oxathiole-2',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase","volume":"89","author":"Balzarini","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ejmech.2018.03.007_bib16","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1021\/jm00093a002","volume":"35","author":"Camarasa","year":"1992","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib17","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1021\/jm991125l","article-title":"Synthesis and evaluation of \u201cAZT-HEPT\u201d. \u201cAZT-pyridinone\u201d and \u201cddC-HEPT\u201d conjugates as inhibitors of HIV reverse transcriptse","volume":"43","author":"Pontikis","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib18","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.bmcl.2007.01.107","article-title":"[d4U]-butyne-[HI-236] as a non-cleavable, bifunctional NRTI\/NNRTI HIV-1 reverse-transcriptase inhibitor","volume":"17","author":"Hunter","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.03.007_bib19","doi-asserted-by":"crossref","first-page":"10270","DOI":"10.1016\/j.bmc.2008.10.048","article-title":"C-2-Aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitors","volume":"16","author":"Hunter","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib20","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1016\/j.bmc.2010.05.025","article-title":"[d4U]-spacer-[HI-236] double-drug inhibitors of HIV-1 reverse-transcriptase","volume":"18","author":"Younis","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib21","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.bmcl.2012.12.015","article-title":"Bifunctional inhibition of HIV-1 reverse transcriptase: a first step in designing a bifunctional triphosphate","volume":"23","author":"Piao","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.03.007_bib22","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1021\/jm400160s","article-title":"Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase: mechanism and proof-of-concept as a novel therapeutic design strategy","volume":"56","author":"Bailey","year":"2013","journal-title":"J.\u00a0Med. Chem"},{"key":"10.1016\/j.ejmech.2018.03.007_bib23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1021\/ml4002979","article-title":"Design, synthesis and antiviral evaluation of chimeric inhibitors of HIV reverse transcriptase","volume":"4","author":"Lyidogan","year":"2013","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.03.007_bib24","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2174\/1381612043384448","article-title":"HIV-1 gp41 as a target for viral entry inhibition","volume":"10","author":"Root","year":"2004","journal-title":"Curr. Pharm. Des"},{"key":"10.1016\/j.ejmech.2018.03.007_bib25","doi-asserted-by":"crossref","DOI":"10.1089\/aid.2006.0277","article-title":"Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249 AIDS Res","volume":"23","author":"Melby","year":"2007","journal-title":"Hum. Retroviruses"},{"key":"10.1016\/j.ejmech.2018.03.007_bib26","doi-asserted-by":"crossref","first-page":"28425","DOI":"10.1074\/jbc.M111.241992","article-title":"A\u00a0novel chimeric protein-based HIV-1 fusion inhibitors targeting gp41 glycoprotein with high potency and stability","volume":"286","author":"Pan","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0092-8674(88)90397-2","article-title":"The CD4 antigen: physiological ligand and HIV receptor","volume":"52","author":"Sattentau","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2018.03.007_bib28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0092-8674(00)80205-6","article-title":"Core structure of gp41 from the HIV envelope glycoprotein","volume":"89","author":"Chan","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2018.03.007_bib29","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1146\/annurev.biochem.70.1.777","article-title":"Mechanisms of viral membrane fusion and its inhibition","volume":"70","author":"Eckert","year":"2001","journal-title":"Annu. Rev. Biochem"},{"key":"10.1016\/j.ejmech.2018.03.007_bib30","doi-asserted-by":"crossref","first-page":"21012","DOI":"10.1074\/jbc.M212773200","article-title":"C-terminal octylation rescues an inactive t20 mutant. Implications for the mechanism of HIV\/simian immunodeficiency virus-induced membrane fusi\u00f3n","volume":"278","author":"Peisajovich","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib31","doi-asserted-by":"crossref","first-page":"11259","DOI":"10.1074\/jbc.M411141200","article-title":"Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120","volume":"280","author":"Liu","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.sbi.2009.07.003","article-title":"Peptides in the treatment of AIDS","volume":"19","author":"Naider","year":"2009","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ejmech.2018.03.007_bib33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/387426a0","article-title":"Atomic structure of the ectodomain from HIV-1 gp41","volume":"387","author":"Weissenhorn","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.03.007_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002797","article-title":"Structural mechanism of trimeric HIV-1 envelope glycoprotein activation","volume":"8","author":"Tran","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ejmech.2018.03.007_bib35","doi-asserted-by":"crossref","first-page":"28370","DOI":"10.1074\/jbc.M111.234799","article-title":"Highly potent chimeric inhibitors targeting two steps of HIV cell entry","volume":"286","author":"Zhao","year":"2011","journal-title":"J.\u00a0Biol.Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0166-3542(96)00945-X","article-title":"Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in\u00a0vitro","volume":"31","author":"Ijichi","year":"1996","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ejmech.2018.03.007_bib37","series-title":"Preparation of Nucleotide Dimers as Anti-HIV Agents","author":"Morozumi","year":"1997"},{"key":"10.1016\/j.ejmech.2018.03.007_bib38","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1081\/NCN-120037749","article-title":"Chemoenzymatic synthesis of homo- and heterodimers of AZT and d4T, and evaluation of their anti-HIV activity","volume":"23","author":"Taourirte","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.ejmech.2018.03.007_bib39","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1021\/jm031045o","article-title":"Hybrids of [TSAO-T]-[foscarnet]: the first conjugate of foscarnet with a non-nucleoside reverse transcriptase Inhibitor through a labile covalent ester bond","volume":"47","author":"Vel\u00e1zquez","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1128\/AAC.42.2.293","article-title":"Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients","volume":"42","author":"Noormohamed","year":"1998","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ejmech.2018.03.007_bib41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1128\/AAC.42.2.293","article-title":"Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients","volume":"42","author":"Noormohamed","year":"1998","journal-title":"Antimicrob. Agents. Chemother"},{"key":"10.1016\/j.ejmech.2018.03.007_bib42","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1021\/jm040845b","article-title":"Synthesis and evaluation of double-prodrugs against HIV. Conjugation of d4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, Emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach","volume":"48","author":"Petersen","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib43","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1021\/jm00020a007","article-title":"Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl phosphate-protecting groups: intracellular delivery of 3\u00b4-azido-2\u00b4,3\u00b4-dideoxythymidine 5\u00b4-monophosphate","volume":"38","author":"Lefebvre","year":"1995","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib44","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/S0960-894X(01)80709-5","article-title":"Rational design for cytosolic delivery of nucleoside monophosphates: \u201cSATE\u201d and \u201cDTE\u201d as enzyme-labile transient phosphate protecting groups","volume":"3","author":"Perigaud","year":"1993","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.03.007_bib45","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/095632029400500605","article-title":"In\u00a0vitro anti-HIV and cytotoxicological evaluation of the triple combination: AZT and ddC with HIV proteinase inhibitor saquinavir (Ro 31-8959)","volume":"5","author":"Craig","year":"1994","journal-title":"Antiviral Chem. Chemother"},{"key":"10.1016\/j.ejmech.2018.03.007_bib46","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.03.007_bib47","first-page":"175","article-title":"Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy","volume":"2","author":"Mathez","year":"1997","journal-title":"Antivir. Ther"},{"key":"10.1016\/j.ejmech.2018.03.007_bib48","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0960-894X(99)00089-X","article-title":"A\u00a0new class of anti-HIV agents: synthesis and activity of conjugates of HIV protease inhibitors with a reverse transcriptase inhibitor","volume":"9","author":"Kimura","year":"1999","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.03.007_bib49","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0968-0896(00)00261-3","article-title":"Synthesis and biological evaluation of prodrug-type anti-HIV agent: ester conjugates of carboxylic acid-containing dipeptide HIV protease inhibitors and a reverse transcriptase inhibitor","volume":"9","author":"Matsumoto","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib50","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/15257779908041638","article-title":"New series of mixed pronucleotides. Synthesis and anti-HIV activities of mononucleoside phenyl SATE phosphotriesters","volume":"18","author":"Schlienger","year":"1999","journal-title":"Nucleos. Nucleot"},{"key":"10.1016\/j.ejmech.2018.03.007_bib51","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0960-894X(00)00202-X","article-title":"`Double-drugs\u00b4- A new class of prodrug form of an HIV Protease Inhibitor conjugate with a reverse transcriptase inhibitor by a spontaneously cleavable linker","volume":"10","author":"Matsumoto","year":"2000","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.03.007_bib52","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/14756360701425386","article-title":"Synthesis of prodrug-type anti-HIV agents conjugating a reverse transcriptase inhibitor to a HIV-1 integrase inhibitor by a spontaneously cleavable linker","volume":"22","author":"Fossey","year":"2007","journal-title":"J.\u00a0Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/095632020201300101","article-title":"In search of authentic inhibitors of HIV-1 integration","volume":"13","author":"Debyser","year":"2002","journal-title":"Antivir. Chem. Chemother"},{"key":"10.1016\/j.ejmech.2018.03.007_bib54","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/14756360412331280554","article-title":"Synthesis and anti-HIV activity of some [nucleoside reverse transcriptase inhibitor]-C5'-linker-[integrase inhibitor] heterodimers as inhibitors of HIV replication","volume":"19","author":"Sugeac","year":"2004","journal-title":"J.\u00a0Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib55","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/14756360701425402","article-title":"Synthesis and anti-HIV evaluation of hybrid-type prodrugs conjugating HIV integrase inhibitors with d4t by self-cleavable spacers containing an amino acid residue","volume":"22","author":"Fossey","year":"2007","journal-title":"J.\u00a0Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib56","first-page":"129","article-title":"The reverse transcriptase of HIV-1: role of the domain connection and RHase H in anti-retroviral resistors","volume":"14","author":"Roquebert","year":"2010","journal-title":"Virologie"},{"key":"10.1016\/j.ejmech.2018.03.007_bib57","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1021\/cb600303y","article-title":"HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazine bound at a novel site","volume":"1","author":"Himmel","year":"2006","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.03.007_bib58","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1742-4658.2011.08057.x","article-title":"Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase (RT)-associated DNA polymerase and ribonuclease H (RNase H) activities effective also on the RNase H activity of non-nucleoside resistant RTs","volume":"278","author":"Esposito","year":"2011","journal-title":"FEBS J"},{"key":"10.1016\/j.ejmech.2018.03.007_bib59","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejmech.2012.01.056","article-title":"Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-2D-fingerprint- and pharmacophore-based virtual screening approach","volume":"50","author":"Distinto","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib60","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1021\/jm900818s","article-title":"Molecular shape and medicinal chemistry: a perspective","volume":"53","author":"Nicholls","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib61","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1016\/j.ccr.2012.07.006","article-title":"Viral enzymes containing magnesium: metal binding as a successful strategy in drug design","volume":"256","author":"Rogolinoa","year":"2012","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.03.007_bib62","doi-asserted-by":"crossref","first-page":"7625","DOI":"10.1128\/JVI.00353-10","article-title":"Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors","volume":"84","author":"Su","year":"2010","journal-title":"J.\u00a0Virol"},{"key":"10.1016\/j.ejmech.2018.03.007_bib63","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ejmech.2015.02.032","article-title":"(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase","volume":"93","author":"Meleddu","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147225","article-title":"Ribonuclease H\/DNA polymerase HIV-1 reverse transcriptase dual inhibior: mechanistic studies on the allosteric mode of action of isatin-based compound RMNC6","volume":"11","author":"Corona","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2018.03.007_bib65","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1021\/jm501132s","article-title":"Design, synthesis, biochemical, and antiviral evaluations of c6 benzyl and c6 biarylmethyl substituted 2-hydroxylisoquinoline-1,3-diones: dual inhibition against HIV reverse transcriptase-associated RNase H and polymerase with antiviral activities","volume":"58","author":"Vernekar","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib66","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1073\/pnas.090521697","article-title":"HIV-1 gp120 and chemokines activate ion channels in primary macrophages through CCR5 and CXCR4 stimulation","volume":"97","author":"Q-Hua","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2018.03.007_bib67","doi-asserted-by":"crossref","first-page":"12996","DOI":"10.1128\/JVI.78.23.12996-13006.2004","article-title":"Inhibition of human immunodeficiency virus replication by dual CCR5\/CXCR4 antagonist","volume":"78","author":"Princen","year":"2004","journal-title":"J.\u00a0Virol"},{"key":"10.1016\/j.ejmech.2018.03.007_bib68","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1017\/S1462399409000921","article-title":"Promiscuous drugs as therapeutics for chemokine receptors","volume":"11","author":"Horuk","year":"2009","journal-title":"Expert. Rev. Mol. Med"},{"key":"10.1016\/j.ejmech.2018.03.007_bib69","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1021\/acsmedchemlett.5b00036","article-title":"Pyrazolo-piperidines exhibit dual inhibition of CCR5\/CXCR4 HIV entry and reverse transcriptase","volume":"6","author":"Cox","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.03.007_bib70","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nature11691","article-title":"Automated design of ligands to polypharmacological profiles","volume":"492","author":"Besnard","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.03.007_bib71","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.2174\/1381612043382648","article-title":"Closely related antiretroviral agents as inhibitors of two HIV-1 enzymes, ribonuclease H and integrase: \u201ckilling two birds with one stone\u201d","volume":"10","author":"Andr\u00e9ola","year":"2004","journal-title":"Curr. Pharm. Des"},{"key":"10.1016\/j.ejmech.2018.03.007_bib72","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1126\/science.2169648","article-title":"Structure of ribonuclease H phased at 2 \u00c5 resolution by MAD analysis of the selenomethionyl protein","volume":"249","author":"Yang","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2018.03.007_bib73","first-page":"1398","article-title":"Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase","volume":"249","author":"Davies","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2018.03.007_bib74","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/AAC.00883-07","article-title":"Madurahydroxylactone derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and RNase H","volume":"52","author":"Marchand","year":"2008","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ejmech.2018.03.007_bib75","doi-asserted-by":"crossref","first-page":"7717","DOI":"10.1021\/jm8007085","article-title":"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain","volume":"51","author":"Billamboz","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib76","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ejmech.2010.11.033","article-title":"1-Hydroxyiwoquinoline-1,3(2H,4H)-diones as inhibitors of HIV-1 integrase and reverse transcriptase RNase H domain: influence of the alkylation of position 4","volume":"56","author":"Billamboz","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib77","doi-asserted-by":"crossref","first-page":"8588","DOI":"10.1021\/jm401040b","article-title":"6-(1-benzyl-1H-pyrool-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach","volume":"56","author":"Costi","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib78","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1021\/jm501799k","article-title":"Structure-activity relationship of pyrrolyl diketo acid derivatives as dual inhibitors of HIV-1 integrase and reverse transcriptase ribonuclease H domain","volume":"58","author":"Cuzzocoli Crucitti","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib79","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.antiviral.2004.11.002","article-title":"6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in\u00a0vitro","volume":"65","author":"Tramontano","year":"2005","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ejmech.2018.03.007_bib80","doi-asserted-by":"crossref","DOI":"10.1021\/jm070512p","article-title":"Rationally designed dual inhibitors of HIV reverse transcriptase and integrase","volume":"50","author":"Wang","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib81","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1075-8593(99)80005-7","article-title":"From an investigation of lithiation of nucleosides towards a rational design of non-nucleoside reverse transcriptase inhibitors of HIV-1","volume":"3","author":"Tanaka","year":"1999","journal-title":"Adv. Antiviral Drug Des"},{"key":"10.1016\/j.ejmech.2018.03.007_bib82","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1126\/science.287.5453.646","article-title":"Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells","volume":"287","author":"Hazuda","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2018.03.007_bib83","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1021\/jm0496077","article-title":"\u03b2-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors","volume":"48","author":"Dayam","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib84","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1073\/pnas.94.8.3984","article-title":"Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside\u2009inhibitor","volume":"94","author":"Esnouf","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2018.03.007_bib85","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1016\/j.bmc.2010.05.004","article-title":"Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase","volume":"18","author":"Wang","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib86","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1016\/j.bmcl.2011.02.069","article-title":"6-Benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV reverse transcriptase and integrase","volume":"21","author":"Tang","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.03.007_bib87","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nrd1660","article-title":"Integrase inhibitors to treat HIV\/AIDS","volume":"4","author":"Pommier","year":"2005","journal-title":"Nat. Rev. Drug. Discov"},{"key":"10.1016\/j.ejmech.2018.03.007_bib88","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nsb0495-303","article-title":"Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors","volume":"2","author":"Esnouf","year":"1995","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.ejmech.2018.03.007_bib89","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1021\/acs.jmedchem.6b00040","article-title":"3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides potently inhibit HIV-1 integrase and RNase H","volume":"59","author":"Wu","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib90","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.mad.2015.09.003","article-title":"The silent war of CMV in aging and HIV infection","volume":"158","author":"Effros","year":"2016","journal-title":"Mech. Ageing. Dev."},{"key":"10.1016\/j.ejmech.2018.03.007_bib91","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1021\/jm040868q","article-title":"Novel [2\u2019,5\u2019-Bis-O-(tert-buthyldimethylsilyl)-\u03b2-D-ribofuranosyl]-3\u00b4-spiro-5\u201d-(4\u201d-amino-1\u201d,2\u201d-oxathiole-2\u201d,2\u201d-dioxide) derivatives with anti-HIV-1 and anti-Human-Cytomegalovirus activity","volume":"48","author":"de Castro","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib92","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1053\/j.gastro.2009.06.040","article-title":"Coinfection with HIV-1 and HCV\u2013a one-two punch","volume":"137","author":"Kim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2018.03.007_bib93","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.3748\/wjg.15.3713","article-title":"Management of hepatitis C virus infection in HIV\/HCV co-infected patients: clinical review","volume":"15","author":"Singal","year":"2009","journal-title":"World J. Gastroenterol"},{"key":"10.1016\/j.ejmech.2018.03.007_bib94","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.bmcl.2010.02.043","article-title":"Discovery of a synthetic dual inhibitor of HIV and HCV infection based on tetrabutoxy-calix[4]arene scaffold","volume":"20","author":"Tsou","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.03.007_bib95","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1182\/blood.V93.12.4232","article-title":"Infection with human immunodeficiency virus-1 increases expression of vascular endothelial cell growth factor in T cells: implications for acquired immunodeficiency syndrome-associated vasculopathy","volume":"93","author":"Ascherl","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2018.03.007_bib96","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1039\/b600720c","article-title":"Biochemistry of the para-sulfonato-calix[n]arenes","author":"Perret","year":"2006","journal-title":"Chem. Commun"},{"key":"10.1016\/j.ejmech.2018.03.007_bib97","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1038\/sj.onc.1208391","article-title":"Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors","volume":"24","author":"Sun","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2018.03.007_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2006.10.006","article-title":"The acyclic nucleoside phosphonates from inception to clinical use: historical perspective","volume":"75","author":"De Clercq","year":"2007","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ejmech.2018.03.007_bib99","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1128\/AAC.32.7.1025","article-title":"Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents","volume":"32","author":"Pauwels","year":"1988","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ejmech.2018.03.007_bib100","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0166-3542(93)90050-S","article-title":"Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection","volume":"21","author":"Heijtink","year":"1993","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ejmech.2018.03.007_bib101","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/AAC.37.2.332","article-title":"Differential antiherpesvirus and antiretrovirus effects of the (s) and (r) enantiomers of acyclic nucleoside phosphonates: potent and selective in\u00a0vitro and in\u00a0vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine","volume":"37","author":"Balzarini","year":"1993","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ejmech.2018.03.007_bib102","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa051214","article-title":"Variant of hepatitis B virus with primary resistance to adefovir","volume":"354","author":"Schildgen","year":"2006","journal-title":"N.\u00a0Engl. J. Med"},{"key":"10.1016\/j.ejmech.2018.03.007_bib103","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.chom.2011.08.015","article-title":"Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication","volume":"20","author":"Andrei","year":"2011","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ejmech.2018.03.007_bib104","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1021\/jm011095y","article-title":"6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity","volume":"45","author":"Hol\u00fd","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib105","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1128\/AAC.49.3.1177-1180.2005","article-title":"Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities","volume":"49","author":"Ying","year":"2005","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ejmech.2018.03.007_bib106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003456","article-title":"A\u00a0multi-targeted drug candidate with dual anti-HIV and anti-HSV activity","volume":"9","author":"Balzarini","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ejmech.2018.03.007_bib107","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1128\/AAC.46.7.2185-2193.2002","article-title":"Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates","volume":"46","author":"Balzarini","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.03.007_bib108","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: a key class of antiviral drugs","volume":"4","author":"De Clercq","year":"2005","journal-title":"Nat. Rev. Drug Discov"},{"key":"10.1016\/j.ejmech.2018.03.007_bib109","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1128\/AAC.49.3.1177-1180.2005","article-title":"Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities","volume":"49","author":"Ying","year":"2005","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ejmech.2018.03.007_bib110","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1074\/jbc.M109.096529","article-title":"The acyclic 2,4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization","volume":"285","author":"Herman","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.03.007_bib111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003456","article-title":"A\u00a0multi-targeted drug candidate with dual anti-HIV and anti-HSV activity","volume":"9","author":"Balzarini","year":"2013","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.ejmech.2018.03.007_bib112","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.antiviral.2015.08.006","article-title":"Conservation of antiviral activity and improved selectivity in PMEO-DAPym upon pyrimidine to triazine scaffold hopping","volume":"122","author":"De Castro","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ejmech.2018.03.007_bib113","first-page":"35","article-title":"Current research and clinical trials for a vaccine against chikungunya virus","volume":"3","author":"Singh","year":"2013","journal-title":"Vaccine: Development and Therapy"},{"key":"10.1016\/j.ejmech.2018.03.007_bib114","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.antiviral.2013.06.009","article-title":"Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy","volume":"99","author":"Thiberville","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ejmech.2018.03.007_bib115","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1021\/np500271u","article-title":"Jatrophane diterpenes as inhibitors of chinkungunya virus replication: structure-activity relationship and discovery of a potent lead","volume":"77","author":"Nothias-Scaglia","year":"2014","journal-title":"J.\u00a0Nat. Prod"},{"key":"10.1016\/j.ejmech.2018.03.007_bib116","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064010","article-title":"The lantibiotic peptide Labyrinthopeptin A1 demonstrates broad anti-HIV and anti-HSV activity with potential for microbicidal applications","volume":"8","author":"F\u00e9rir","year":"2013","journal-title":"PLoS One"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418302423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418302423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:45:10Z","timestamp":1759326310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418302423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":115,"alternative-id":["S0223523418302423"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.03.007","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polypharmacology in HIV inhibition: can a drug with simultaneous action against two relevant targets be an alternative to combination therapy?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}